// App-Quantinova.ai

TPS4608 : A phase III randomized trial of eribulin (E) with or without gemcitabine versus standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab) SWOG S1937.

Researchers

Presenter

  • Sarmad Sadeghi

Principal Investigators

  • Melissa Plets

  • Primo "Lucky" N. Lara

  • Catherine Tangen

  • Rick Bangs

  • Seth P. Lerner

  • Thomas W. Flaig

  • Daniel P. Petrylak

  • Ian Thompson

Medical Centers

  • University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

  • SWOG Statistics and Data Management Center, Seattle, WA

  • University of California, San Francisco, CA

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • Bladder Cancer Advocacy Network, Bethesda, MD

  • Baylor College of Medicine, Houston, TX

  • University of Colorado Cancer Center, Aurora, CO

  • Yale Cancer Center, New Haven, CT

  • Christus Health, San Antonio, TX.

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Urology

  • Oncology (ONC)

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Gemcitabine

  • Paclitaxel

  • Docetaxel

  • Eribulin

Outcome

  • N/A

Study Design

  • Randomized

  • Multiple Arm

Phase

  • III

Study Id's

  • NCT04579224

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved